Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) - Total Liabilities

Latest as of March 2026: CN¥3.71 Billion CNY ≈ $542.17 Million USD

Based on the latest financial reports, Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) has total liabilities worth CN¥3.71 Billion CNY (≈ $542.17 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 603707 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Nanjing King-friend Biochemical Pharmaceutical Co Ltd - Total Liabilities Trend (2013–2025)

This chart illustrates how Nanjing King-friend Biochemical Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Nanjing King-friend Biochemical Pharmace (603707) total assets.

Nanjing King-friend Biochemical Pharmaceutical Co Ltd Competitors by Total Liabilities

The table below lists competitors of Nanjing King-friend Biochemical Pharmaceutical Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
Ningbo PIA Automation Holding Corp. A
SHG:688306
China CN¥2.93 Billion
Westone Information Industry Inc
SHE:002268
China CN¥1.59 Billion
H&R Real Estate Investment Trust
TO:HR-UN
Canada CA$4.97 Billion
Monadelphous Group Ltd
F:8MP
Germany €421.77 Million
Shaanxi Ligeance Mineral Resources Co Ltd
SHE:000697
China CN¥1.16 Billion
ZAI LAB LTD0000006
F:1ZLB
Germany €433.76 Million
Kumho Petro Chemical
KO:011780
Korea ₩2.32 Trillion
Hunan Aihua Group Co Ltd
SHG:603989
China CN¥2.23 Billion

Liability Composition Analysis (2013–2025)

This chart breaks down Nanjing King-friend Biochemical Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Nanjing King-friend Biochemical Pharmace's balance sheet to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.27 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.53 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.35 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Nanjing King-friend Biochemical Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Nanjing King-friend Biochemical Pharmaceutical Co Ltd (2013–2025)

The table below shows the annual total liabilities of Nanjing King-friend Biochemical Pharmaceutical Co Ltd from 2013 to 2025.

Year Total Liabilities Change
2025-12-31 CN¥3.44 Billion
≈ $503.85 Million
+13.95%
2024-12-31 CN¥3.02 Billion
≈ $442.18 Million
-18.89%
2023-12-31 CN¥3.73 Billion
≈ $545.20 Million
-3.05%
2022-12-31 CN¥3.84 Billion
≈ $562.34 Million
+36.56%
2021-12-31 CN¥2.81 Billion
≈ $411.80 Million
-29.22%
2020-12-31 CN¥3.98 Billion
≈ $581.78 Million
+91.67%
2019-12-31 CN¥2.07 Billion
≈ $303.54 Million
+111.40%
2018-12-31 CN¥981.21 Million
≈ $143.58 Million
+52.72%
2017-12-31 CN¥642.50 Million
≈ $94.02 Million
+208.75%
2016-12-31 CN¥208.09 Million
≈ $30.45 Million
+1.65%
2015-12-31 CN¥204.72 Million
≈ $29.96 Million
-59.72%
2014-12-31 CN¥508.26 Million
≈ $74.37 Million
+265.89%
2013-12-31 CN¥138.91 Million
≈ $20.33 Million
--

About Nanjing King-friend Biochemical Pharmaceutical Co Ltd

SHG:603707 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.82 Billion
CN¥12.44 Billion CNY
Market Cap Rank
#6517 Global
#1307 in China
Share Price
CN¥7.70
Change (1 day)
-2.65%
52-Week Range
CN¥6.84 - CN¥10.47
All Time High
CN¥33.62
About

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. It also provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium besylate, cisatracurium, calcium folinate, doxorubicin, milrinone, bleomycin, carboplatin, cytarabine, topotecan hydrochloride, phenylephrine hydrochlo… Read more